$2.49
0.00% today
Nasdaq, Nov 21, 04:20 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Target price 2024 - Analyst rating & recommendation

CureVac N.V. Classifications & Recommendation:

Buy
43%
Hold
43%
Sell
14%

CureVac N.V. Price Target

Target Price $6.79
Price $2.49
Potential
Number of Estimates 6
6 Analysts have issued a price target CureVac N.V. 2025 . The average CureVac N.V. target price is $6.79. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 3 Analysts recommend CureVac N.V. to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CureVac N.V. stock has an average upside potential 2025 of . Most analysts recommend the CureVac N.V. stock at Buy or hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 58.12 562.13
17.98% 867.19%
EBITDA Margin -473.92% 43.67%
23.15% 109.21%
Net Margin -490.21% 34.92%
12.20% 107.12%

5 Analysts have issued a sales forecast CureVac N.V. 2024 . The average CureVac N.V. sales estimate is

$562m
Unlock
. This is
5.65% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$576m 3.39%
Unlock
, the lowest is
$552m 7.37%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $58.1m 17.98%
2024
$562m 867.19%
Unlock
2025
$58.0m 89.68%
Unlock
2026
$151m 159.82%
Unlock
2027
$156m 3.45%
Unlock
2028
$152m 2.20%
Unlock

3 Analysts have issued an CureVac N.V. EBITDA forecast 2024. The average CureVac N.V. EBITDA estimate is

$245m
Unlock
. This is
19.00% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$285m 38.12%
Unlock
, the lowest is
$225m 9.12%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-275m 1.00%
2024
$245m 189.13%
Unlock
2025
$-105m 142.76%
Unlock
2026
$-31.4m 70.06%
Unlock
2027
$-68.5m 117.87%
Unlock

EBITDA Margin

2023 -473.92% 23.15%
2024
43.67% 109.21%
Unlock
2025
-180.97% 514.40%
Unlock
2026
-20.85% 88.48%
Unlock
2027
-43.92% 110.65%
Unlock

3 CureVac N.V. Analysts have issued a net profit forecast 2024. The average CureVac N.V. net profit estimate is

$196m
Unlock
. This is
59.08% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$273m 120.92%
Unlock
, the lowest is
$145m 17.55%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-285m 7.97%
2024
$196m 168.89%
Unlock
2025
$-120m 161.36%
Unlock
2026
$-67.2m 44.18%
Unlock
2027
$-85.1m 26.55%
Unlock

Net Margin

2023 -490.21% 12.20%
2024
34.92% 107.12%
Unlock
2025
-207.62% 694.56%
Unlock
2026
-44.61% 78.51%
Unlock
2027
-54.57% 22.33%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.27 0.87
7.97% 168.50%
P/E 2.85
EV/Sales negative

3 Analysts have issued a CureVac N.V. forecast for earnings per share. The average CureVac N.V. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.87
Unlock
. This is
58.18% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$1.22 121.82%
Unlock
, the lowest is
$0.65 18.18%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.27 7.97%
2024
$0.87 168.50%
Unlock
2025
$-0.54 162.07%
Unlock
2026
$-0.30 44.44%
Unlock
2027
$-0.38 26.67%
Unlock

P/E ratio

Current 4.53 223.77%
2024
2.85 37.09%
Unlock
2025
-4.64 262.81%
Unlock
2026
-8.31 79.09%
Unlock
2027
-6.57 20.94%
Unlock

Based on analysts' sales estimates for 2024, the CureVac N.V. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-0.02
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.02 100.11%
2024
-0.02 2.00%
Unlock
2025
-0.20 871.08%
Unlock
2026
-0.08 61.53%
Unlock
2027
-0.07 3.28%
Unlock
2028
-0.08 2.31%
Unlock

P/S ratio

Current 0.94 96.57%
2024
0.99 6.00%
Unlock
2025
9.63 869.10%
Unlock
2026
3.71 61.51%
Unlock
2027
3.58 3.34%
Unlock
2028
3.66 2.25%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today